Loading…
Delta Kozmetik Sanayi Ve Ticaret-Selim Yesil, a Turkish pharmaceutical manufacturer, failed to comply with Current Good Manufacturing Practice (CGMP) regulations for finished drugs, rendering their products adulterated. During a September 2022 inspection, the FDA identified critical violations including failure to test incoming components for identity and conformity with specifications, inadequate supplier qualification, and failure to validate suppliers' test analyses at appropriate intervals. The company's October 2022 response to the inspection findings was deemed inadequate as it lacked sufficient detail and evidence of corrective actions necessary to achieve compliance.